Here's why the Rhythm (ASX:RHY) share price is soaring 8% today

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22. Here's what the company announced to the ASX.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price is on the run following the company's strategic update to FY22.

During early morning trade, Rhythm shares are swapping hands for $1.045, up 8.8%.

Rhythm moves ahead with strategic plans

Investors appear to be pleased with the company's progress to commercialise its cancer detection technology, ColoSTAT, driving Rhythm shares higher.

In its announcement, Rhythm highlighted a number of activities that it is moving forward to launch ColoSTAT into global markets.

The first of its listed strategic initiatives is to accelerate United States market entry for ColoSTAT. The company has incorporated a wholly-owned entity to cement its foothold in the country to carry operations out smoothly. The initial pathway stages to obtain market approval from the United States Food and Drug Administration (FDA) has already commenced.

In addition, Rhythm has expanded its platform by setting up an Australian entity to hold its technology within. The company validated initial data that its lead biomarker has a global market opportunity for cancer diagnostics.

Regulatory entry in both Europe (CE Mark) and Australia is advancing ahead of completion in its ColoSTAT Study 7. CE Mark filing is slated for late 2021, and the Australian Therapeutic Goods Administration (TGA) has begun the regulatory approval process.

Lastly, the company is looking at further market entry strategies in Europe, Australia, New Zealand, China, and broader Asia. Further updates in regards to this are expected to be released to the ASX in the coming months.

Notably, the company is targeting its first revenue for late 2022.

Comments from the CEO

Rhythm CEO, Mr. Glenn Gilbert commented:

Following the exceptional ColoSTAT performance results from Study 6 and the LRF algorithm enhancement work, this has given the company confidence to now accelerate the execution of our commercial strategy, focusing on our path to market activities.

ColoSTAT will transform the global mass-market cancer diagnostic market, with exciting and positive impacts at a social and economic level.

About the Rhythm share price

The Rhythm share price has been one of the best performers over the last 12 months, rising more than 1,000%. The company's shares were trading at 6.3 cents in June before accelerating later that year.

It's worth noting that the Rhythm share price is trading just below its all-time high of $1.675, reached in March.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two scientists looking at a tablet.
Healthcare Shares

CSL shares are up more than 40% in a month. What just happened in the US?

The stock’s huge rebound is getting another boost.

Read more »

Woman flexes muscles after donating blood.
ASX Share Market News

Where will CSL shares be in 12 months? Brokers weigh in

Analysts remain divided over CSL’s recovery prospects.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Why this ASX healthcare share is a retiree's dream for FY27

This defensive business is giving investors rising dividends.

Read more »

Two scientists analysing results on a computer screen.
Broker Notes

Up 88%! Why CSL shares remain an 'appealing' buy today

A top analyst forecasts more outperformance from CSL’s surging shares.

Read more »

Two scientists analysing results on a computer screen.
Earnings Results

Monash IVF Group earnings: FY26 profit slips, outlook improves

The company posted weaker FY26 profit but ends year with improving momentum, dividend, and outlook for growth.

Read more »

Happy investor on tablet with finance graphs rising in overlay.
Healthcare Shares

Bell Potter says this ASX healthcare share could rise 200%+

The broker has good things to say about this growing stock.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

4DMedical share price rises as FY26 revenue climbs, losses moderate

4DMedical lifted revenue 21% and improved its adjusted net loss for FY26, while investing in new AI-driven medical imaging solutions.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Imricor Medical Systems and Philips launch MR-guided cardiac interventions lab

Imricor Medical Systems has teamed up with Philips to launch a new MR-guided cardiac interventions lab, targeting broader clinical adoption.

Read more »